Physician profile
Stacey Pun
NPI 1851763783
$2,920.67
in general payments reported to CMS, 2019-2025
20 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what 92% of Dermatopathology (Pathology) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.71 · 2023: $449 · 2024: $1,056 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.97 |
| Education | $297.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $569.43 | 2023-2025 | Tremfya |
| Genzyme Corporation | $348.58 | 2021-2025 | |
| Incyte Corporation | $308.04 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $247.27 | 2023-2025 | Winlevi, Ilumya |
| Leo Pharma INC. | $219.64 | 2023-2025 | Adbry, Anzupgo |
| Pfizer INC. | $195.86 | 2024-2025 | |
| Ucb, INC. | $188.08 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $160.72 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Abbvie INC. | $147.12 | 2021-2025 | |
| Amgen INC. | $100.62 | 2023-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $99.87 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $59.23 | 2024-2025 | Zoryve |
| Botanix Sb INC | $51.45 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $51.17 | 2025 | |
| Galderma Laboratories, L.P. | $38.62 | 2025 | Nemluvio |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $36.71 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $32.57 | 2025 | Genadur |
| Paratek Pharmaceuticals, INC. | $22.96 | 2024 | Nuzyra |
| Verrica Pharmaceuticals INC. | $22.27 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.46 | 2025 | Jublia, Cabtreo, Siliq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Pun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.